Summary
Pharmaceuticals in the Netherlands industry profile provides top-line qualitative and quantitative summary information including: market size (value 2014-18, and forecast to 2023). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Highlights
- The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare.
- The Dutch pharmaceuticals market had total revenues of $5.1m in 2018, representing a compound annual rate of change (CARC) of -4.1% between 2014 and 2018.
- The performance of the market is forecast to follow a similar pattern with an anticipated CARC of -4.3% for the five-year period 2018-2023, which is expected to drive the market to a value of $4.1m by the end of 2023.
- The fall of the pound and the influence of NHS reference pricing has caused an unexpected Brexit-bonus to Dutch healthcare expenditure.
Scope
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in the Netherlands
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in the Netherlands
- Leading company profiles reveal details of key pharmaceuticals market players’ global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the Netherlands pharmaceuticals market with five year forecasts
Reasons to buy
- What was the size of the Netherlands pharmaceuticals market by value in 2018?
- What will be the size of the Netherlands pharmaceuticals market in 2023?
- What factors are affecting the strength of competition in the Netherlands pharmaceuticals market?
- How has the market performed over the last five years?
- How large is the Netherlands’s pharmaceuticals market in relation to its regional counterparts?
'
Table of Contents
Executive Summary
Market value
Market value forecast
Geography segmentation
Market share
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market Segmentation
Geography segmentation
Market share
Market Outlook
Market value forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
AstraZeneca PLC
GlaxoSmithKline Plc
Novartis AG
Pfizer Inc
Macroeconomic Indicators
Country data
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine
List of Tables
Table 1: Netherlands pharmaceuticals market value: $ billion, 2014-18
Table 2: Netherlands pharmaceuticals market geography segmentation: $ billion, 2018
Table 3: Netherlands pharmaceuticals market share: % share, by value, 2018
Table 4: Netherlands pharmaceuticals market value forecast: $ billion, 2018-23
Table 5: AstraZeneca PLC: key facts
Table 6: AstraZeneca PLC: key financials ($)
Table 7: AstraZeneca PLC: key financial ratios
Table 8: GlaxoSmithKline Plc: key facts
Table 9: GlaxoSmithKline Plc: key financials ($)
Table 10: GlaxoSmithKline Plc: key financials (£)
Table 11: GlaxoSmithKline Plc: key financial ratios
Table 12: Novartis AG: key facts
Table 13: Novartis AG: key financials ($)
Table 14: Novartis AG: key financial ratios
Table 15: Pfizer Inc: key facts
Table 16: Pfizer Inc: key financials ($)
Table 17: Pfizer Inc: key financial ratios
Table 18: Netherlands size of population (million), 2014-18
Table 19: Netherlands gdp (constant 2005 prices, $ billion), 2014-18
Table 20: Netherlands gdp (current prices, $ billion), 2014-18
Table 21: Netherlands inflation, 2014-18
Table 22: Netherlands consumer price index (absolute), 2014-18
Table 23: Netherlands exchange rate, 2014-18
List of Figures
Figure 1: Netherlands pharmaceuticals market value: $ billion, 2014-18
Figure 2: Netherlands pharmaceuticals market geography segmentation: % share, by value, 2018
Figure 3: Netherlands pharmaceuticals market share: % share, by value, 2018
Figure 4: Netherlands pharmaceuticals market value forecast: $ billion, 2018-23
Figure 5: Forces driving competition in the pharmaceuticals market in the Netherlands, 2018
Figure 6: Drivers of buyer power in the pharmaceuticals market in the Netherlands, 2018
Figure 7: Drivers of supplier power in the pharmaceuticals market in the Netherlands, 2018
Figure 8: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the Netherlands, 2018
Figure 9: Factors influencing the threat of substitutes in the pharmaceuticals market in the Netherlands, 2018
Figure 10: Drivers of degree of rivalry in the pharmaceuticals market in the Netherlands, 2018
Figure 11: AstraZeneca PLC: revenues & profitability
Figure 12: AstraZeneca PLC: assets & liabilities
Figure 13: GlaxoSmithKline Plc: revenues & profitability
Figure 14: GlaxoSmithKline Plc: assets & liabilities
Figure 15: Novartis AG: revenues & profitability
Figure 16: Novartis AG: assets & liabilities
Figure 17: Pfizer Inc: revenues & profitability
Figure 18: Pfizer Inc: assets & liabilities
